BridgeMD
A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL)
EU CTIS ID: 2024-520123-83-01
What this study is testing
To determine, in patients with relapsed or refractory cHL, the rate of complete response (CR) to ruxolitinib in combination with brentuximab (Cohort-1) or pembrolizumab (Cohort-2), reached during ruxolitinib treatment or at the end of ruxolitinib treatment.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Cohort-1: ruxolitinib + brentuximab 1.This cohort is open to adult patients with CD30+ cHL relapsed or refractory after autologous stem cell transplantation (ASCT), or after at least two previous lines of treatment if ASCT or polichemotherapy do not represent treatment options (as per AIFA label of brentuximab).
- Immuno-histologically proven diagnosis of classical Hodgkin lymphoma
- At least one measurable tumor lesion on PET-CT
- Availability of the whole paraffin block (or, less preferably, at least 30 paraffin sections) of an adequately sized excisional tumor biopsy (archival and/or newly performed) for mandatory centralized assessment of response biomarkers
- Availability of a baseline whole-blood sample of 40 ml for mandatory centralized assessment of response biomarkers
- ECOG performance status: 0-1 for Cohort-1; 0-2 for Cohort-2 (as per AIFA registry)
You likely can't join if
- Previous treatment of cHL with ruxolitinib or another JAK inhibitor received before enrollment in the trial
- [for Cohort-2 only] Therapy with systemic immunosuppressive agents (which would be blocked by the AIFA registry of pembrolizumab, except for doses ≤ 10 mg/day of prednisone or equivalent corticosteroids) must have been stopped since at least 2 weeks
- Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption. Patients must be able to swallow capsules.
- CNS involvement by lymphoma
- Currently uncontrolled active infection
- Other severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may, in the judgment of the clinical investigator and/or the Sponsor, increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or may make the patient inappropriate for entry into this study
See the full eligibility criteria
Who can join
- Cohort-1: ruxolitinib + brentuximab 1.This cohort is open to adult patients with CD30+ cHL relapsed or refractory after autologous stem cell transplantation (ASCT), or after at least two previous lines of treatment if ASCT or polichemotherapy do not represent treatment options (as per AIFA label of brentuximab).
- Immuno-histologically proven diagnosis of classical Hodgkin lymphoma
- At least one measurable tumor lesion on PET-CT
- Availability of the whole paraffin block (or, less preferably, at least 30 paraffin sections) of an adequately sized excisional tumor biopsy (archival and/or newly performed) for mandatory centralized assessment of response biomarkers
- Availability of a baseline whole-blood sample of 40 ml for mandatory centralized assessment of response biomarkers
- ECOG performance status: 0-1 for Cohort-1; 0-2 for Cohort-2 (as per AIFA registry)
- Life expectancy ≥ 5 months
- Any prior anti-lymphoma treatment (e.g., chemotherapy, radiotherapy, immunotherapy, investigational agents) must have been completed at least 4 weeks prior to initiation of study medication, except if no response to, or progression on, this treatment is already manifestly evident earlier
- Signed informed consent prior to performing any study-related procedures
- Cohort-1: ruxolitinib + brentuximab_2. Even when fulfilling the criteria of point 1 above, patients cannot be enrolled if: i) They had previously received an allotransplant (as they would be blocked by the AIFA registry for brentuximab); ii) or they can receive less than 8 infusions of brentuximab through the AIFA registry (due to previous infusions of the drugs through the registry); iii) or they had progressed on brentuximab after activating the AIFA registry for this drug (because progression on brentuximab recorded in the AIFA registry would block further requests of the drug through this registry). However, patients fulfilling the criteria of point 1 above can be enrolled if they progressed on brentuximab before activating the AIFA registry (as no record of progression would be present in this registry and the patients might benefit from combining ruxolitinib to brentuximab).
- Cohort-1: ruxolitinib + brentuximab_3. If complying with the criteria of points 1 and 2 above, patients progressing after previous treatment in Cohort-2 may be enrolled in Cohort-1 upon decision of the Sponsor in conjunction with the clinical investigator(s).
- Cohort-1: ruxolitinib + brentuximab_ 4. If complying with the criteria of points 1 and 2 above, patients taken off Cohort-2 due to important toxicity from pembrolizumab may be enrolled in Cohort-1, upon decision of the Sponsor in conjunction with the clinical investigator(s), as long as they have not responded (i.e., no PR or CR) to the treatment received in Cohort- 2.
- Cohort-2: ruxolitinib + pembrolizumab 1. This cohort is open to adult patients with relapsed or refractory cHL previously treated with both ASCT or with at least two prior therapies when ASCT is not a treatment option (as per AIFA label of pembrolizumab).
- Cohort-2: ruxolitinib + pembrolizumab_ 2. Patients fulfilling the criteria of point 1 above can be enrolled even if they had previously received an allotransplant (which does not block the AIFA registry for pembrolizumab), but they cannot be enrolled if they had previously received a PD1 or PDL1 inhibitor (which blocks the AIFA registry)
- Cohort-2: ruxolitinib + pembrolizumab_ 3. If complying with the criteria of points 1 and 2 above, patients progressing after previous treatment in Cohort-1 may be enrolled in Cohort-2 upon decision of the Sponsor in conjunction with the clinical investigator(s).
- Cohort-2: ruxolitinib + pembrolizumab_ 4. If complying with the criteria of points 1 and 2 above, patients taken off Cohort-1 due to important toxicity from brentuximab may be enrolled in Cohort-2, upon decision of the Sponsor in conjunction with the clinical investigator(s), as long as they have not responded (i.e., no PR or CR) to the treatment received in Cohort- 1
- ≥ 18 years of age
What rules you out
- Previous treatment of cHL with ruxolitinib or another JAK inhibitor received before enrollment in the trial
- [for Cohort-2 only] Therapy with systemic immunosuppressive agents (which would be blocked by the AIFA registry of pembrolizumab, except for doses ≤ 10 mg/day of prednisone or equivalent corticosteroids) must have been stopped since at least 2 weeks
- Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption. Patients must be able to swallow capsules.
- CNS involvement by lymphoma
- Currently uncontrolled active infection
- Other severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may, in the judgment of the clinical investigator and/or the Sponsor, increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or may make the patient inappropriate for entry into this study
- Pregnant or lactating females, or patients who are not willing to use an adequate method of birth control until 6 month after the last dose of brentuximab or pembrolizumab
- Inability to comply with other requirements of the protocol
- [for Cohort-2 only] Previous treatment with a PD1/PDL1 inhibitor, as per AIFA registry on pembrolizumab
- [for Cohort-2 only] Symptomatic interstitial lung disease or active autoimmune disease (except for vitiligo, type-1 diabetes, hypothyroidism secondary to autoimmune thyroiditis requiring hormonal replacement therapy, and psoriasis not requiring systemic treatmentystemic treatment), as per AIFA registry of pembrolizumab; or active graft-versus-host disease after allo-transplantation.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.